Cinctive Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cinctive Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,462	Closed	-$2.41M	–	710
2021 Q4	$2.41M	Buy	+17,462	New	+$2.22M	0.11%	277
2021 Q3	–	Sell	-69,614	Closed	-$6.76M	–	698
2021 Q2	$6.76M	Sell	69,614 -20,836	-23%	-$1.69M	0.32%	96
2021 Q1	$6.18M	Buy	+90,450	New	+$7.32M	0.38%	77
2020 Q4	–	Sell	-24,270	Closed	-$1.58M	–	437
2020 Q3	$1.58M	Buy	+24,270	New	+$1.59M	0.14%	231

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Cinctive Capital Management's BHVN Position: Q1 2022 in Review

Cinctive Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 17,462 shares — an estimated $2.41M sold.

Cinctive Capital Management first reported a position in BHVN in Q3 2020 and held it in 4 quarters. The position peaked at $6.76M in Q2 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

Cinctive Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
Cinctive Capital Management sold 17,462 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $2.41M.
Cinctive Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2020 and held it in 4 quarters.
Cinctive Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.76M in Q2 2021.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Cinctive Capital Management's 13F filing for Q1 2022, filed 16 May 2022.